跳到正文
原文
U.S. FDA· @FDA · X·· 8 天前精选AI 评分80
AI 导读

FDA 向患者和医务人员通报,使用 GLP-1 RA 药物可能与非动脉炎性前部缺血性视神经病变(NAION)风险升高相关。NAION 是一种罕见疾病,可导致单眼急性无痛性视力下降,甚至永久性视力丧失,症状包括晨起发现的单眼突发无痛性视力丧失、盲点、颜色失真、视物模糊或管状视野。FDA 要求对 GLP-1 受体激动剂进行安全标签修改,患者出现上述症状应立即联系医务人员。

推荐理由

FDA 就 GLP-1 RA 与 NAION 的潜在风险发布安全信息并要求修改标签,读者可据此了解该类药物新增的用药警示。

正文

Today, we are informing patients and health care providers of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with use of GLP-1 RA medications.
NAION is a rare condition that can result in acute, painless, decreased vision in one eye, including permanent vision loss. Symptoms of NAION include sudden, painless vision loss in one eye that patients may notice upon waking: visual defects such as blind spots, distortion of colors, blurriness, or tunnel vision.

Patients should contact their health care professional right away if they have any of these symptoms. https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential

来源:U.S. FDA · x.com